Semaglutide-associated NAION in T2DM patient linked to optic disc drusen and hypohydration, proposing 'two-hit' model.
Background
Non-arteritic anterior ischaemic optic neuropathy (NAION) is a leading cause of acute vision loss in older adults, characterized by infarction of the optic nerve head. Its exact mechanisms remain unclear, but it is often associated with systemic vascular risk factors. Recent observational studies have presented conflicting evidence regarding a potential association between semaglutide use and NAION, prompting a need for deeper mechanistic understanding. Current standard-of-care for Type 2 Diabetes focuses on glycemic control, but the potential ocular side effects of newer agents like semaglutide warrant investigation, especially in susceptible individuals.
Study Design
Researchers reported a case of a 28-year-old man with Type 2 Diabetes who developed right NAION 4-5 months after initiating semaglutide. The patient underwent comprehensive ophthalmic evaluation, including multimodal imaging to confirm the diagnosis of NAION and identify pre-existing anatomical risk factors. Serial bioimpedance measurements were performed over 7 weeks to assess changes in body fluid compartments, specifically total body water (TBW) and extracellular-to-total-body-water (ECW/TBW) ratio, to investigate potential links between hydration status and the onset of NAION.
Results
The patient presented with acute vision loss in his right eye, which was subsequently diagnosed as NAION through multimodal imaging. This imaging also revealed the presence of bilateral buried optic disc drusen, an anatomical predisposition for NAION, with the affected right eye being short and the fellow eye highly myopic and longer. Crucially, serial bioimpedance measurements demonstrated a significant decline in the patient's total body water (TBW) by 1.9 L over a 7-week period. This reduction occurred while fat mass remained preserved and the extracellular-to-total-body-water (ECW/TBW) ratio was stable, suggesting a sustained state of hypohydration rather than a shift in fluid distribution. The authors propose a 'two-hit' model:
Anatomical susceptibility (buried optic disc drusen) combined with sustained hypohydration (potentially exacerbated by semaglutide's effects on appetite/thirst or direct renal effects) together precipitate NAION.
Key Findings
- A 28-year-old man developed right NAION 4-5 months after initiating semaglutide.
- Patient exhibited bilateral buried optic disc drusen, an anatomical risk factor for NAION.
- Serial bioimpedance showed a 1.9 L decline in total body water over 7 weeks.
- A 'two-hit' model is proposed, combining anatomical susceptibility and sustained hypohydration.
Why It Matters
This case report highlights a potential, albeit rare, adverse event associated with semaglutide and offers a plausible mechanistic 'two-hit' model involving pre-existing anatomical risk and hydration status. For peptide users and clinicians, this suggests a need for heightened clinical awareness regarding NAION symptoms, particularly in patients with known risk factors like optic disc drusen or those experiencing significant weight loss and potential changes in hydration. While this is a single case, it underscores the importance of monitoring hydration status in individuals on GLP-1 agonists, especially if they have underlying ocular predispositions. Further prospective studies are required to validate this hypothesis and determine if specific patient populations require closer ophthalmic monitoring or hydration guidance when initiating semaglutide.
semaglutide
naion
optic-disc-drusen
hypohydration
type-2-diabetes
case-report